Back

T cell-derived IFNγ instructs ECM crosslinking by cardiac fibroblasts through LOXL3 in experimental cardiometabolic HFpEF

Emig, R.; Robbe, Z. L.; Kley, C.; Smolgovsky, S.; Travers, J. G.; Blanton, R. M.; McKinsey, T. A.; Black, L. D.; Alcaide, P.

2026-03-18 pathology
10.64898/2026.03.16.712110 bioRxiv
Show abstract

BackgroundHeart failure with preserved ejection fraction (HFpEF) is a major clinical challenge characterized by diastolic dysfunction. Left ventricular stiffening and inflammation are hallmarks of HFpEF, yet the contribution of extracellular matrix (ECM) stiffness and the immune-stromal mechanisms driving ECM stiffening in cardiometabolic HFpEF remain poorly understood. MethodsWe used the murine "2-hit model" of cardiometabolic HFpEF, in which the combination of high fat diet and hypertension induced by L-NAME causes diastolic dysfunction. We evaluated diastolic function by echocardiography and ECM mechanics by uniaxial tensile testing of decellularized cardiac tissue. Functional in vivo studies included genetic depletion of T cells, interferon-{gamma} (IFN{gamma}) knockout mice, and pharmacological lysyl oxidase inhibition. We combined co-cultures of CD4+ T cells and cardiac fibroblasts (CFB) with mechanical testing of cardiac ECM and molecular biology to elucidate cellular and molecular mechanisms. ResultsLeft ventricular ECM stiffness strongly correlated with impaired diastolic function in experimental cardiometabolic HFpEF. Cardiac CD4 T cell infiltration was required for ECM stiffening and upregulation of lysyl oxidase enzymes in CFB. CD4+ T cell-derived IFN{gamma} was both necessary and sufficient to induce LOXL3 in CFB, which increased ECM stiffness in vitro. Mechanistically, IFN{gamma} signaling activated hypoxia-inducible factor-1 (HIF1) in CFB, driving LOXL3 expression and subsequent collagen crosslinking. Genetic or pharmacologic disruption of this IFN{gamma}-HIF1-LOXL3 axis in vivo attenuated adverse ECM remodeling and improved diastolic function. ConclusionsCD4 T cells promote pathological ECM stiffening in cardiometabolic HFpEF through IFN{gamma}-mediated, LOXL3-dependent ECM crosslinking by CFB. Targeting this immune-stromal pathway may offer a novel therapeutic strategy for HFpEF.

Matching journals

The top 5 journals account for 50% of the predicted probability mass.

1
Circulation
66 papers in training set
Top 0.2%
17.3%
2
Circulation Research
39 papers in training set
Top 0.1%
12.2%
3
JCI Insight
241 papers in training set
Top 0.1%
12.2%
4
Circulation: Heart Failure
14 papers in training set
Top 0.1%
7.1%
5
Journal of Clinical Investigation
164 papers in training set
Top 0.2%
6.7%
50% of probability mass above
6
Cardiovascular Research
33 papers in training set
Top 0.1%
6.2%
7
Arteriosclerosis, Thrombosis, and Vascular Biology
65 papers in training set
Top 0.6%
4.3%
8
Journal of the American Heart Association
119 papers in training set
Top 2%
4.2%
9
American Journal of Physiology-Heart and Circulatory Physiology
32 papers in training set
Top 0.3%
3.5%
10
Journal of the American Society of Nephrology
52 papers in training set
Top 0.3%
2.0%
11
Journal of Molecular and Cellular Cardiology
39 papers in training set
Top 0.5%
1.7%
12
PLOS ONE
4510 papers in training set
Top 59%
1.3%
13
Science Translational Medicine
111 papers in training set
Top 4%
1.3%
14
Nature Communications
4913 papers in training set
Top 57%
1.2%
15
JACC: Basic to Translational Science
15 papers in training set
Top 0.3%
1.2%
16
European Heart Journal
16 papers in training set
Top 0.6%
0.9%
17
Scientific Reports
3102 papers in training set
Top 71%
0.9%
18
Frontiers in Cardiovascular Medicine
49 papers in training set
Top 2%
0.8%
19
Disease Models & Mechanisms
119 papers in training set
Top 3%
0.7%
20
Journal of Cellular and Molecular Medicine
18 papers in training set
Top 1%
0.7%
21
Journal of the American College of Cardiology
12 papers in training set
Top 0.8%
0.6%